AbbVie Receives Designation for Upadacitinib as Rare Disease Treatment for Takayasu Arteritis

AbbVie Gains Rare Disease Status for Upadacitinib in Takayasu Arteritis

AbbVie, headquartered in Minato-ku, Tokyo, recently announced that it has received a rare disease designation from Japan’s Ministry of Health, Labour and Welfare for its drug Upadacitinib, aimed at treating Takayasu arteritis when existing treatments fail to provide sufficient relief. This marked a significant milestone for the company as the new designation enhances the therapeutic options available for patients suffering from this challenging condition.

Takayasu arteritis is characterized by inflammation of the aorta and its main branches, affecting vital arteries including the coronary and pulmonary arteries. This rare large vessel vasculitis can lead to severe complications due to narrowed or blocked blood vessels, ultimately disrupting blood flow to critical organs such as the heart, brain, kidneys, and lungs. The estimated number of patients in Japan with Takayasu arteritis is around 5,000, predominantly affecting women aged around 20 years. Every year, approximately 200 to 300 new cases are reported, highlighting the urgency for effective treatments.

Currently, conventional therapies for Takayasu arteritis include corticosteroids and IL-6 inhibitors. However, these options are limited and often result in high relapse rates, particularly when corticosteroid doses are reduced or discontinued. Patients frequently experience relapses even after achieving temporary remission with traditional immune-suppressing treatments. The evolving treatment landscape necessitates innovative solutions to address the needs of those whose conditions do not adequately respond to existing pharmacotherapies.

About Upadacitinib

Upadacitinib is a selective JAK inhibitor developed by AbbVie, which acts as a low-molecular-weight oral treatment administered once daily. The drug has demonstrated its effectiveness across multiple immune-mediated diseases. By preferentially inhibiting signaling pathways mediated by JAK1 or JAK1/3 over JAK2, Upadacitinib offers a targeted therapeutic approach.

Since receiving its first approval in Japan for treating adult patients with insufficient response to current therapies for rheumatoid arthritis in January 2020, Upadacitinib has obtained additional indications for several conditions. These include treatment-resistant psoriatic arthritis, atopic dermatitis, ankylosing spondylitis, and ulcerative colitis in varying stages of severity, culminating in its recent approval in June 2023 for managing moderate to severe active Crohn's disease.

With the new designation for Takayasu arteritis, AbbVie continues to innovate in areas of unmet medical need, aiming to improve the quality of life for patients grappling with chronic health challenges.

AbbVie’s Commitment

AbbVie’s mission revolves around solving pressing health issues through the creation and provision of innovative therapies. The company prioritizes its research and development efforts in key therapeutic areas including immunology, oncology, neuroscience, and aesthetics, backed by a commitment to enhancing individual lives. For more information about AbbVie’s endeavors, visit www.abbvie.com and engage with their community across platforms like Facebook, Instagram, Twitter, YouTube, and LinkedIn.

In Japan, AbbVie’s focus extends to various domains including immune disorders, liver diseases, mental health, and cancer care, as well as aesthetic medical products under the Allergan Aesthetics portfolio. Further details can be found at www.abbvie.co.jp.